Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 1/2 1

Status

Completed 8Recruiting 4Withdrawn 2Unknown 2Not yet recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other solid neoplasm 54Other hematologic neoplasm 28Breast 27Gastrointestinal 24Thoracic 23Lymphoid 21Genitourinary 14Gynecologic 11Myeloid 10CNS 5Plasma cell 4Head & Neck 4NET 3Endocrine 3Tumor-Agnostic 2Sarcoma 2Dermatologic 2Classical hematology 2Other 1

Conditions

Multiple Myeloma 4Recurrence 1

Interventions

Dexamethasone 98daratumumab 57Lenalidomide 53Bortezomib 38pomalidomide 37Cyclophosphamide 37carfilzomib 25Calcium Dobesilate 25fludarabine 22talquetamab 19iberdomide 18isatuximab 17Specimen Handling 17Magnetic Resonance Spectroscopy 17Biopsy 15selinexor 13dexamethasone acetate 12belantamab mafodotin 12Melphalan 12dexamethasone 21-phosphate 11auricularum 10venetoclax 8fludarabine phosphate 7elotuzumab 7X-Rays 6tocilizumab 5Blood Specimen Collection 5ruxolitinib 4ixazomib 4Trimethoprim, Sulfamethoxazole Drug Combination 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Injections × Plasma cell × Clear all
NCT05020236 2026-05-05

MAGNETISMM-5

Pfizer

Phase 3 Recruiting
944 enrolled
Plasma cell

Multiple Myeloma

NCT06484777 2026-04-16

A Clinical Study of SHR-9539 in Patients With Multiple Myeloma

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 1 Recruiting
138 enrolled
Plasma cell

Multiple Myeloma

NCT06574568 2026-02-05

A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma

Excyte Biopharma Ltd

Phase 1 Recruiting
70 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT06049290 2025-12-04

A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma

Nanjing Leads Biolabs Co.,Ltd

Phase 1/2 Recruiting
342 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡